OBJECTIVE: To review systematically, for the first time, the effectiveness of all pharmacologic interventions to improve quality of life and well-being in people with dementia. DESIGN: Systematic review and meta-analysis. METHODS: We systematically reviewed the 15 randomized controlled trials and one review that fitted predetermined criteria. We included studies that reported the outcomes quality of life, well-being, happiness, or pleasure. MEASUREMENTS: We rated the validity of studies using a checklist. We calculated mean differences between intervention and control groups at follow-up. RESULTS: None of the evaluated trials reported a significant benefit to quality of life or well-being for people with dementia when comparing those taking a drug or its comparator at follow-up (pooled weighted mean difference: 0.18 [95% confidence interval: -0.82 to 0.46]). CONCLUSION: We found no consistent evidence that any drug improves quality of life in people with dementia. We recommend that all dementia trials should include quality of life as an outcome, as this is important to patients, and cannot be presumed from improvements in cognition or other symptomatic outcomes, especially if the latter are small.
OBJECTIVE: To review systematically, for the first time, the effectiveness of all pharmacologic interventions to improve quality of life and well-being in people with dementia. DESIGN: Systematic review and meta-analysis. METHODS: We systematically reviewed the 15 randomized controlled trials and one review that fitted predetermined criteria. We included studies that reported the outcomes quality of life, well-being, happiness, or pleasure. MEASUREMENTS: We rated the validity of studies using a checklist. We calculated mean differences between intervention and control groups at follow-up. RESULTS: None of the evaluated trials reported a significant benefit to quality of life or well-being for people with dementia when comparing those taking a drug or its comparator at follow-up (pooled weighted mean difference: 0.18 [95% confidence interval: -0.82 to 0.46]). CONCLUSION: We found no consistent evidence that any drug improves quality of life in people with dementia. We recommend that all dementia trials should include quality of life as an outcome, as this is important to patients, and cannot be presumed from improvements in cognition or other symptomatic outcomes, especially if the latter are small.
Authors: Joshua D Niznik; Xinhua Zhao; Meiqi He; Sherrie L Aspinall; Joseph T Hanlon; David Nace; Joshua M Thorpe; Carolyn T Thorpe Journal: Alzheimers Dement Date: 2020-02-13 Impact factor: 21.566
Authors: Barbara Resnick; Ann Kolanowski; Kimberly Van Haitsma; Elizabeth Galik; Marie Boltz; Jeanette Ellis; Liza Behrens; Nina M Flanagan; Karen J Eshraghi; Shijun Zhu Journal: Res Nurs Health Date: 2018-02-27 Impact factor: 2.228
Authors: Daniel R Bateman; Bhavana Srinivas; Thomas W Emmett; Titus K Schleyer; Richard J Holden; Hugh C Hendrie; Christopher M Callahan Journal: J Med Internet Res Date: 2017-08-30 Impact factor: 5.428
Authors: Barbora Silarova; Sharon M Nelis; Rosalie M Ashworth; Clive Ballard; Marta Bieńkiewicz; Catherine Henderson; Alexandra Hillman; John V Hindle; Julian C Hughes; Ruth A Lamont; Rachael Litherland; Ian R Jones; Roy W Jones; Martin Knapp; Piers Kotting; Anthony Martyr; Fiona E Matthews; Robin G Morris; Catherine Quinn; Jemma Regan; Jennifer M Rusted; Eleanor Ann van den Heuvel; Christina R Victor; Yu-Tzu Wu; Linda Clare Journal: BMC Public Health Date: 2018-10-30 Impact factor: 3.295